JPS61109725A - Ointment - Google Patents

Ointment

Info

Publication number
JPS61109725A
JPS61109725A JP23203084A JP23203084A JPS61109725A JP S61109725 A JPS61109725 A JP S61109725A JP 23203084 A JP23203084 A JP 23203084A JP 23203084 A JP23203084 A JP 23203084A JP S61109725 A JPS61109725 A JP S61109725A
Authority
JP
Japan
Prior art keywords
aragonite
ointment
skin
lime
sweat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP23203084A
Other languages
Japanese (ja)
Inventor
Kamehiko Mogi
茂木 亀彦
Masashi Gondaira
權平 昌司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HIMENO TORU
Original Assignee
HIMENO TORU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HIMENO TORU filed Critical HIMENO TORU
Priority to JP23203084A priority Critical patent/JPS61109725A/en
Publication of JPS61109725A publication Critical patent/JPS61109725A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:An ointment useful for preventing skin inflammations such as bedsore, prickly heat, etc. and remedying them in an early stage, absorbing sweat, dissolving it gradually, neutralizing acidity of sweat, keeping the skin weakly alkali, containing lime carbonate of Aragonite type. CONSTITUTION:An ointment capable of preventing occurrence of skin inflammations and bedsore, containing lime carbonate of Aragonite type. Its content is properly 3-15(W/W)%. Lime carbonate of Aragonite type derived from Aragonite, calcareous tufa, coral, etc. may be used as the line carbonate of Aragonite type. The lime carbonate of Aragonite absorbs sweat, dissolves it gradually, neutralizes acidity of sweat, and keeps the skin weakly alkali. Moreover, neutralizing effect continues, so the ointment is extremely effective for preventing skin inflammations such as bedsore, prickly heat, etc. and remedying them in an early stage.

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明は皮膚の炎症の発生を防止し、床ずれを予防でき
る軟膏に関するものである。
DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to an ointment that can prevent the occurrence of skin inflammation and prevent bedsores.

〔従来の技術〕[Conventional technology]

人間の皮膚から分泌される汗はpH3,5〜4.5の酸
性を示す。これは、寄生虫、mVJ等に対し一種の殺菌
作用を現すものである。
Sweat secreted from human skin has an acidic pH of 3.5 to 4.5. This exhibits a kind of bactericidal action against parasites, mVJ, etc.

しかし、皮膚の弱っている老人、特に寝たきり老人等は
汗の酸性により皮膚に炎症を生じ、所謂床ずれとなり、
寝たきり老人及び周囲の大人を悩ませている。
However, in elderly people with weakened skin, especially bedridden elderly people, the acidity of sweat causes inflammation of the skin, resulting in so-called bedsores.
This causes trouble for the bedridden elderly and the adults around them.

これらの炎症の治療のために従来は種々の軟膏、散布剤
等が使用されている。
Conventionally, various ointments, sprays, etc. have been used to treat these inflammations.

〔発明が解決しようとする問題点〕[Problem that the invention seeks to solve]

しかしながら、従来から使用されている軟膏、や散布剤
はあせも或は細菌性又はアレルギー性の炎症には奏効し
ても床ずれには殆ど効果がなかった。
However, conventionally used ointments and sprays are effective against heat rash, bacterial or allergic inflammation, but have little effect on bedsores.

〔問題点を解決するための手段〕[Means for solving problems]

上述の問題点を解決するため本発明では、軟膏の一成分
としてアラゴナイト型炭酸石灰を含有せしめた。
In order to solve the above-mentioned problems, the present invention includes aragonite-type lime carbonate as one of the components of the ointment.

ここでアラゴナイト型炭酢石灰とは以下の如きものであ
る。
Here, the aragonite type charcoal lime is as follows.

炭酸石灰(CaCO,)を主成分とする鉱石には方解石
、石灰石、白を等があるが、水には殆ど溶解しない。し
かし、炭酸ガス(Co、)を多く含有する水には下記式 %式%) の(1にヒドロ炭酸石灰が生じて可溶性になり、溶解す
る度合がやや大きくなる。
Ore whose main component is lime carbonate (CaCO) includes calcite, limestone, white, etc., but it is hardly soluble in water. However, in water containing a large amount of carbon dioxide gas (Co), hydrocarbonate lime is formed in (1) of the following formula (% formula %) and becomes soluble, and the degree of dissolution becomes somewhat large.

ヒドロ炭酢石灰を溶解した水は除々に大気中に炭酸ガス
を放出し、炭山石灰を析出する。この析出した炭山石灰
が少しづつ堆積し、巨大な石状になったものが鍾乳石で
あり、何メートルにもなった大きいものは同千年もかか
つて出来たものである。
The water in which hydrocharcoal vinegar lime is dissolved gradually releases carbon dioxide gas into the atmosphere, and precipitates coalwood lime. This precipitated coal mountain lime is deposited little by little and becomes huge stone-like stones called stalactites, and the large ones that are several meters long were formed about 1,000 years ago.

又、ヒドロ炭酸石灰を溶解した水の温度が高く又地中の
土圧が高いため、通常よりヒドロ炭M石仄の溶解量が多
い温水が、地上に出現したとき温度の下降と土圧の減少
により水中から析出したものが、一般にいわれている温
泉の石灰湯薙である。
In addition, because the temperature of the water in which hydrocarbonate lime is dissolved is high and the earth pressure underground is high, when warm water with a larger amount of dissolved hydrocarbonate lime than usual appears on the ground, the temperature will drop and the earth pressure will decrease. What is precipitated from the water due to the decrease is what is generally called hot spring lime yunagi.

炭酸石灰は結晶型により二つの同質異性体がある。一つ
は六力晶壓系のカルサイト(Calcite)であり、
方解石、白〒、石灰石、大理石等はこれに屈し、殆ど水
には溶解しない。
Lime carbonate has two homoisomers depending on its crystal type. One is calcite of the hexagonal crystalline system,
Calcite, white stone, limestone, marble, etc. succumb to this and hardly dissolve in water.

もう一つは斜方晶型系のアラゴナイト(^raga −
n i tc)であり、アラレ石はこれに屈し、曲記石
灰湯菫或はサンゴ中にも比較的多量に含まれており、カ
ルサイト型に比較して水に稍溶解し易い性質を有してい
る。特に炭酸ガス含有量の多い水にはよく溶解し、pi
が弱アルカリ性(pH7,4〜7.6)を呈する。
The other type is orthorhombic aragonite (^raga -
Araleite succumbs to this and is also contained in relatively large amounts in violets and corals, and has the property of being slightly more soluble in water than the calcite type. are doing. It dissolves particularly well in water with a high carbon dioxide content, and pi
exhibits weak alkalinity (pH 7.4 to 7.6).

本発明で使用するアラゴナイト型炭酸石灰は。The aragonite type carbonate lime used in the present invention is:

アラレ石、石灰flA’JJ、サンゴ等の由来のものを
使用することができる。
Materials derived from aralite, lime flA'JJ, coral, etc. can be used.

アラゴナイト型炭酸石灰は比較的軟質多孔性であるが、
皮膚に対してザラザラした感じを与えず且つ溶は易くす
るため、出来るだけ微細な粉末にして用いるとよい。
Aragonite-type carbonate lime is relatively soft and porous;
In order to avoid giving a rough feeling to the skin and to make it easier to dissolve, it is best to use it in the form of as fine a powder as possible.

その他の成分としては、酸化亜鉛(徴求)、精製ラノリ
ン、サラシミツロウ、白色ワセリン等の亜鉛症軟膏に用
いられる成分の他、一般の軟膏に使用される成分を配合
することができる。
As other ingredients, in addition to ingredients used in zincosis ointments such as zinc oxide (refined), purified lanolin, white beeswax, and white petrolatum, ingredients used in general ointments can be blended.

更に、81M剤、抗ヒスタミン剤等の他の薬物を配合す
ることもできる。
Furthermore, other drugs such as 81M agents and antihistamines can also be blended.

アラゴナイト型炭酸石灰の含有量は総固型分に対し3〜
15(W/W)%が適当である。アラゴナイト型炭爵石
灰の含有量が少なすぎると、汗のPHをアルカリ性にす
る°ことができず、又カルシウム濃度もg過ぎて効果が
弱い。又、アラゴナイト型炭酸石灰の含有量が多過ぎる
と使用感が低下する。
The content of aragonite-type carbonate lime is 3 to 3% of the total solid content.
15 (W/W)% is appropriate. If the content of aragonite-type carbonaceous lime is too small, it will not be possible to make the pH of sweat alkaline, and the calcium concentration will be too high, making the effect weak. Moreover, if the content of aragonite-type lime carbonate is too large, the feeling of use will deteriorate.

本発明の軟膏は常法により製することができる。The ointment of the present invention can be manufactured by conventional methods.

本発明の軟膏は背中、F!或は首筋等の皮膚にel X
i? rR布することにより使用する。
The ointment of the present invention can be applied to the back, F! Or use elX on the skin of the neck etc.
i? Use by rR cloth.

〔作   用〕[For production]

本発明の軟膏を皮膚に塗布すると、軟膏中に分散された
アラゴナイト型炭酸石灰は皮膚表面に存在するが、汁の
ない状態ではアラゴナイト型炭酸石灰は殆ど溶解しない
ため、略中性であり皮膚に対し何の刺激も与えることは
ない。
When the ointment of the present invention is applied to the skin, the aragonite-type lime carbonate dispersed in the ointment exists on the skin surface, but since the aragonite-type lime carbonate hardly dissolves in the absence of juice, it is almost neutral and does not affect the skin. It doesn't provide any stimulation.

発汗により軟膏中のアラゴナイト型炭階石灰が汗を吸収
するとアラゴナイト型炭酸石灰が僅かに溶解し、汗の削
性を中和し皮膚表面は洞アルカリ性に保たれる。
When the aragonite-type carbonate lime in the ointment absorbs sweat due to sweating, the aragonite-type carbonate lime dissolves slightly, neutralizing the abrasiveness of sweat and keeping the skin surface alkaline.

従って、汗による炎症の発生が防止され、床ずれが防止
される。
Therefore, inflammation caused by sweat is prevented, and pressure sores are prevented.

〔実 施 例〕〔Example〕

以下に、実施例を示して本発明の@膏を更に具体的に説
明するが、本発明はこれらに限定されるものではない。
The present invention will be described in more detail below with reference to Examples, but the present invention is not limited thereto.

実施例1 酸化亜鉛〔徴求)       20g精製ラノリン 
       l1g サラシミツロウ        4g 白色ワセリン        62g アラゴナイト型炭巾石灰    3g 合   計             100g常法に
より軟膏を製する。
Example 1 Zinc oxide (required) 20g purified lanolin
l1g White beeswax 4g White vaseline 62g Aragonite-type charcoal lime 3g Total 100g Make an ointment using a conventional method.

実施例2 酸化t#、鉛(徴求)       20g精製ラノリ
ン        l1g サラシミツロウ        4g 白色ワセリン         60gアラゴナイト型
炭酸石灰    5g 合   計              1 00g実
施例1と同様の方法により軟膏を製する。
Example 2 T# oxide, lead (required) 20 g Refined lanolin 1 g White beeswax 4 g White petrolatum 60 g Aragonite type carbonate lime 5 g Total 100 g An ointment is prepared in the same manner as in Example 1.

実施例3 重化亜鉛(徴求)       zag精製ラノリン 
       l1g サラシミツロウ        4g 白色ワセリン        55g アラゴナイトq炭巾石灰   10g 合   計              100 g実
施例1と@J様の方法により軟膏を製する。
Example 3 Heavy zinc (request) zag purified lanolin
l1g White beeswax 4g White vaseline 55g Aragonite q charcoal lime 10g Total 100g An ointment is made by the method of Example 1 and @J.

実施例4 重化亜鉛(徴求)       zog精製ラノリン 
       11g サラシミツロウ        4g 白色ワセリン        sog アラゴナイト型炭市石灰   15g 合   計             100g実施例
1と同様の方法により軟膏を製する。
Example 4 Heavy Zinc (Request) Zog Purified Lanolin
11g White beeswax 4g White petrolatum sog Aragonite type charcoal lime 15g Total 100g An ointment is prepared in the same manner as in Example 1.

〔発明の効果〕〔Effect of the invention〕

以上述べたように本発明の軟膏によれば、アラゴナイト
型炭M石灰を含有せしめたので、皮四表面に9布された
!膏中のアラゴナイト型炭酸石灰が皮屑から発汗された
汗を吸収して溶解し、汗の酸性を中和し皮屑を弱アルカ
リ性に保持することができ、且つアラゴナイト型炭酸石
灰は少!dずつ溶けるため汁の中和効果が長時間持続す
るので、床ずれ、あせも等皮腐炎症の予防、早期治療に
極めて有用である等の稀々の優れた効果を発揮する。
As described above, since the ointment of the present invention contains aragonite-type charcoal M lime, it can be applied to all four surfaces of the skin. The aragonite-type carbonate lime in the paste absorbs and dissolves sweat from the skin debris, neutralizing the acidity of sweat and keeping the skin debris slightly alkaline, and the amount of aragonite-type carbonate lime is small! Since the neutralizing effect of the juice lasts for a long time because it dissolves by 1.5 d, it exhibits rare and excellent effects such as being extremely useful for the prevention and early treatment of skin rotting inflammation such as bedsores and heat rash.

Claims (1)

【特許請求の範囲】 1)アラゴナイト型炭酸石灰を含有することを特徴とす
る軟膏。 2)アラゴナイト型炭酸石灰の含有量が3〜15(W/
W)%である特許請求の範囲第1項記載の軟膏。
[Claims] 1) An ointment characterized by containing aragonite-type lime carbonate. 2) The content of aragonite type carbonate lime is 3 to 15 (W/
W)%.
JP23203084A 1984-11-02 1984-11-02 Ointment Pending JPS61109725A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP23203084A JPS61109725A (en) 1984-11-02 1984-11-02 Ointment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23203084A JPS61109725A (en) 1984-11-02 1984-11-02 Ointment

Publications (1)

Publication Number Publication Date
JPS61109725A true JPS61109725A (en) 1986-05-28

Family

ID=16932864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP23203084A Pending JPS61109725A (en) 1984-11-02 1984-11-02 Ointment

Country Status (1)

Country Link
JP (1) JPS61109725A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801570A4 (en) * 1994-12-21 1998-12-30 Cosmederm Technologies Formulations and methods for reducing skin irritation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801570A4 (en) * 1994-12-21 1998-12-30 Cosmederm Technologies Formulations and methods for reducing skin irritation

Similar Documents

Publication Publication Date Title
CA1254150A (en) Dentifrice for hypersensitive teeth
US6149947A (en) Compositions of oak bark extract related synthetic compositions and method of using same
HUP0104747A2 (en) Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
DE69409006T2 (en) PRECURSOR COMPOSITION AND CERIUM AND ZIRCONIUM MIXED OXIDE COMPOSITION, THEIR PRODUCTION METHOD AND APPLICATION
BG102722A (en) Biologically active vitreous compositions and method for their treatment making use of biologically active glass
CA2158475A1 (en) Composition and method for reducing toxicity of biologically-active factors
ATE287704T1 (en) ORODISPERSIBLE TABLET WITH HIGH HOMOGENEITY AND PRODUCTION PROCESS THEREOF
HUP0100090A2 (en) Oral care composition
SE8504754D0 (en) PROCEDURE FOR MANUFACTURING BUILDING MATERIAL
IT1262993B (en) RITNITINE AND ANTIBIOTIC BISMUTO CITRATE COMPLEX, COMPOSITION CONTAINING IT AND RELATED METHOD OF PRODUCTION AND USE
ES8206974A1 (en) Non-yellowing topical pharmaceutical composition.
MY109531A (en) Effervescent antacid
WO2000010999A3 (en) New compounds
US4917889A (en) Topical composition and treatment
JPS61109725A (en) Ointment
Ho et al. Presynaptic actions of Mojave toxin isolated from Mojave rattlesnake (Crotalus scutulatus) venom
MX9701187A (en) Novel n-substituted naphthofused lactams.
EP0736033A4 (en) Novel therapeutic carbohydrate blends useful for aiding premenstrual syndrome
Elder Recent experimental and clinical studies on the pharmacology of colloidal bismuth subcitrate
JPS61109726A (en) Conspergative
DE69424679D1 (en) COMPOSITION FOR TREATING OR PREVENTING HERPES
TW261613B (en)
DE60015135D1 (en) PROLACTIN RELEASING PEPTIDE AND USE FOR TREATMENT OF PAIN
ES8702134A1 (en) Agent for increasing the pH of dental plaque and process for preparing it.
JPS5650104A (en) Treatment of water containing phosphate